OR WAIT null SECS
Almac?s Clinical Services business unit announced the addition of refrigerated reusable shippers to its portfolio of solutions for the management and global distribution of temperature controlled clinical supplies.
’s Clinical Services business unit announced the addition of refrigerated reusable shippers to its portfolio of solutions for the management and global distribution of temperature controlled clinical supplies. Available as an option to replace single-use shippers for refrigerated shipments, 2°C to 8°C, the reusable shippers can reduce shipping and storage costs while maintaining payload capacity.
This latest addition is complementary to its range of
cold chain management
solutions which include a global team of Cold Chain Experts, a strategic depot network, over 3,000 pallets of dedicated, refrigerated storage facilities, and a proprietary Shipping Temperature Electronic Monitoring System (STEMS) allowing for same day temperature data.
Features of the reusable shippers include identical product space with a smaller overall volume than single-use shippers, thus reducing shipping and storage costs. In addition, the environmental impact caused by single-use shippers is virtually eliminated, and clients will benefit from the removal of tedious destruction processes often required with single-use shippers.
Commenting on the latest enhancement, Leon Supplee, Director of Logistics at Almac’s US headquarters in Souderton, PA stated, “With an increase in biologics and temperature sensitive shipments, Almac strives to offer the best in temperature-controlled distribution. The addition of reusable shippers is one more way that Almac has risen to meet the changing needs of our clients and provide further efficiencies in the supply chain.”
Almac also plans to release reusable options for controlled, ambient shipments, 15°C to 25°C and frozen shipments, -25°C to -15°C in the near future.
For more information on our full suite of cold chain solutions and how reusable shipper options can benefit your next clinical trial please contact